{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-24-000162","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.454766+00:00","generated_at":"2026-05-31T05:55:46.692867+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunovant reports 76% response rate in Graves' Disease Phase 2a; IND cleared for IMVT-1402 pivotal trial","bullets":["High-dose batoclimab (680 mg SC weekly) achieved 76% response rate and 56% ATD-free response at week 12 in patients uncontrolled on antithyroid drugs.","Lower-dose batoclimab (340 mg) yielded 68% response and 36% ATD-free response; 70%+ IgG reduction linked to nearly 3x higher ATD-free response.","FDA IND cleared; pivotal trial of IMVT-1402 in Graves' Disease expected to initiate by December 31, 2024.","Real-world claims data indicate 25–30% of GD patients per year are uncontrolled on ATDs with limited existing therapeutic options."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-24-000162","json":"https://secwatch.observer/filing/0001764013-24-000162.json","markdown":"https://secwatch.observer/filing/0001764013-24-000162.md","text":"https://secwatch.observer/filing/0001764013-24-000162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000162/0001764013-24-000162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000162/imvt-20240909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:55:46.692867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}